Sanofi-Aventis transfers US Actonel rights to Warner Chilcott
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has transferred the US and Puerto Rican rights to the osteoporosis treatment Actonel (risedronate sodium) to Warner Chilcott.